Marvel Biosciences Secures NRC IRAP Grant for Pediatric MB-204 Liquid Formulation
Marvel Biosciences secured funding and advisory services from NRC IRAP to develop a pediatric-friendly liquid formulation of its lead compound MB-204 for neurodevelopmental disorders. The project targets small-volume dosing suitable for children with autism spectrum disorder, Rett syndrome and Fragile X syndrome to improve accessibility and adherence.
1. NRC IRAP Funding Secured
Marvel Biosciences received advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program to support R&D of a pediatric liquid formulation of MB-204.
2. Focus on Pediatric Neurodevelopmental Disorders
The program will develop a small-volume oral liquid for children and adolescents with autism spectrum disorder, Rett syndrome and Fragile X syndrome who face challenges swallowing pills or using solid forms.
3. Formulation Development Strategy
Multiple liquid approaches will be evaluated to ensure stability, reproducibility and accurate dosing via oral syringe or feeding tube without compromising drug exposure.
4. Strategic R&D and IP Expansion
This initiative enhances Marvel’s IP portfolio, retains high-value pharmaceutical R&D in Canada and generates data to support upcoming pediatric clinical trials and regulatory engagements.